Clinical Trial of Lactiplantibacillus Plantarum Dad-13 on Gut Microbiota Profile and Performance in Adolescent Athletes

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age12-18
SponsorGadjah Mada University

About this trial

The aim of this research is to analyze the effect of a Lactiplantibacillus plantarum Dad-13 supplementation on the gut microbiota profile and performance of adolescent athletes.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Residing in the BPPLOP dormitory of Central Java Province;

Having a normal body mass index;

Being an athlete in an endurance sport;

Having no growth disorders

Disqualifiers

Injury, any health contraindication or failure to perform exercise procedures;

Gastrointestinal infections, diseases, disorders;

Past history of gastrointestinal surgery;

Failure to follow the study protocol;

Trial design

Design model

Single group

Treatments tested in this trial

  • Probiotic Lactiplantibacillus plantarum Dad-13

    Dietary supplement

    Lactiplantibacillus plantarum Dad-13 is an indigenous probiotic strain isolated from the curd produced by spontaneous fermentation of buffalo milk in bamboo containers and originates from Minangkabau, West Sumatra, Indonesia.

Treatment groups

30 Participants
are divided into 1 treatment group
Group A: Control groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

gut microbiota profile

Gut microbiota profiles were measured from fecal samples, then isolated using 16S rDNA sequencing. Fecal samples were collected in the morning. Results: alfa and beta diversity

Time frame
From pre treatment and the end of treatment at 8 weeks
2

Short chain fatty acid profile

The total level or amount of short chain fatty acid metabolites produced from the fermentation process in the intestine obtained from feces. Results: Total amount of SCFA, acetic acid, propionic acid, butyric acid

Time frame
pre treatment and end of treatment at 8 weeks
3

Physical Performance

The physical performance measurement used was VO2max. The VO2max measurement method used a direct laboratory method with COSMED K5 before and after the intervention, with units of kg/mL.

Time frame
pre treatment and the end of treatment at 8 weeks

Secondary outcomes

1

Fecal calprotectin concentration

Protein in white blood cells that acts as an inflammation marker with measurement using ELISA. Fecall samples was used.

Time frame
pre treatment and the end of treatment at 8 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: